OncologyClinical Data ManagementPhase III

Reducing Database Lock Time by 40% on a Phase III Oncology Study

Global Oncology Sponsor

40%

Faster database lock

98%

Query resolution rate

6 weeks

Submission delay avoided

01

The Challenge

A global Phase III oncology sponsor faced a backlog of 4,200 outstanding queries at the 90-day pre-lock window, threatening a 6-week submission delay.

02

The IDDCR Approach

IDDCR deployed AI Companion Tools to automate query generation and triage, combined with a dedicated CDM surge team operating across three time zones.

03

The Outcome

Database lock achieved 40% ahead of the revised schedule. Outstanding queries reduced from 4,200 to under 80 at lock. Submission timeline fully recovered.

40% — Faster database lock
98% — Query resolution rate
6 weeks — Submission delay avoided

"IDDCR's CDM team and their AI tooling turned what looked like an insurmountable query backlog into a non-event. The lock came in ahead of even our optimistic scenario."
VP Clinical Operations
Global Oncology Sponsor

More Case Studies

View All

Rare Disease

CDISC SDTM Automation Across a 12-Study Rare Disease Programme

Read Case Study

Neurology

End-to-End Trial Management for a 22-Country Phase II Neurology Study

Read Case Study

Rare DiseaseCDISC StandardsPhase II / III

CDISC SDTM Automation Across a 12-Study Rare Disease Programme

Rare Disease Biotech

60%+

Reduction in programming effort

12

Studies delivered on schedule

0

Critical FDA validation findings

01

The Challenge

A rare disease biotech needed SDTM-compliant datasets across 12 studies with heterogeneous EDC configurations, facing an FDA submission deadline in 14 months.

02

The IDDCR Approach

iClinicalAI was configured to automate SDTM mapping, validation and define.xml authoring across all 12 studies, with IDDCR statistical programmers providing oversight and regulatory review.

03

The Outcome

Programming effort reduced by over 60%. All 12 study SDTM packages delivered on time. Zero critical Pinnacle 21 findings at FDA review.

60%+ — Reduction in programming effort
12 — Studies delivered on schedule
0 — Critical FDA validation findings

"The iClinicalAI-driven SDTM automation gave us a level of consistency and speed across 12 studies that would have been impossible with a traditional programming approach."
Head of Biometrics
Rare Disease Biotech

More Case Studies

View All

Oncology

Reducing Database Lock Time by 40% on a Phase III Oncology Study

Read Case Study

Neurology

End-to-End Trial Management for a 22-Country Phase II Neurology Study

Read Case Study

NeurologyClinical Trial ManagementPhase II

End-to-End Trial Management for a 22-Country Phase II Neurology Study

Neurology Sponsor

3 weeks

Ahead of enrolment target

42 days

Median site activation

<2%

Protocol deviation rate

01

The Challenge

A mid-size neurology sponsor required full-service CRO support for a 22-country, 340-patient Phase II study with complex eligibility criteria and a 12-month enrolment target.

02

The IDDCR Approach

IDDCR provided end-to-end trial management including site selection, CRA oversight, risk-based monitoring, and real-time enrolment analytics via a bespoke CTMS dashboard.

03

The Outcome

Enrolment target met 3 weeks ahead of schedule. Site activation median reduced to 42 days. Protocol deviation rate held below 2% across all sites.

3 weeks — Ahead of enrolment target
42 days — Median site activation
<2% — Protocol deviation rate

"IDDCR's proactive site management and real-time enrolment visibility gave us confidence throughout. We hit our enrolment target early — a first for this programme."
Clinical Programme Director
Neurology Sponsor

More Case Studies

View All

Oncology

Reducing Database Lock Time by 40% on a Phase III Oncology Study

Read Case Study

Rare Disease

CDISC SDTM Automation Across a 12-Study Rare Disease Programme

Read Case Study

Infectious DiseaseBiostatisticsPhase II / III

Adaptive Design Biostatistics Support for a Phase II/III Infectious Disease Study

Infectious Disease Biotech

18 days

SAP delivery

100%

On-time interim analysis

FDA accepted

Adaptive design at EoP2

01

The Challenge

A sponsor required biostatistics support for a seamless Phase II/III adaptive design with an interim analysis, requiring rapid turnaround of the SAP and blinded sample size re-estimation.

02

The IDDCR Approach

IDDCR's biostatistics team authored the SAP, pre-specified the adaptive decision rules, and executed the blinded interim analysis in collaboration with an independent DMC statistician.

03

The Outcome

SAP delivered in 18 days. Interim analysis completed on schedule. Adaptive design accepted by FDA without modification at end-of-Phase II meeting.

18 days — SAP delivery
100% — On-time interim analysis
FDA accepted — Adaptive design at EoP2

"The IDDCR biostatistics team's expertise in adaptive designs was evident from the first call. Their SAP was thorough, and the FDA's acceptance of our design was a major milestone."
Chief Medical Officer
Infectious Disease Biotech

More Case Studies

View All

Oncology

Reducing Database Lock Time by 40% on a Phase III Oncology Study

Read Case Study

Rare Disease

CDISC SDTM Automation Across a 12-Study Rare Disease Programme

Read Case Study

Neurology

End-to-End Trial Management for a 22-Country Phase II Neurology Study

Read Case Study

Establishing a Pharmacovigilance Signal Detection Programme for a Cardiovascular Portfolio

The Challenge

The IDDCR Approach

The Outcome

More Case Studies

Reducing Database Lock Time by 40% on a Phase III Oncology Study

CDISC SDTM Automation Across a 12-Study Rare Disease Programme

End-to-End Trial Management for a 22-Country Phase II Neurology Study

Establishing a Pharmacovigilance Signal Detection Programme for a Cardiovascular Portfolio

Adaptive Design Biostatistics Support for a Phase II/III Infectious Disease Study